Algernon已提交Pre-IND申请,以进行Ifenprodil治疗新冠肺炎的临床试验

2020-03-14 Allan MedSci原创

临床阶段药物开发公司Algernon Pharmaceuticals宣布,已向美国FDA提交Pre-IND申请。

临床阶段药物开发公司Algernon Pharmaceuticals宣布,已向美国FDA提交Pre-IND申请。这将启动与美国FDA的正式沟通,以推进NP-120(Ifenprodil)治疗COVID-19感染相关的急性肺损伤(ALI)和急性呼吸窘迫综合征。

在申请中,Algernon已就使用新的注射和缓释制剂提供了指导。这项申请文件还包括对扩展访问路径(也称为“同情使用”路径)的说明。

最近的一项独立研究发现,在NP-120(Ifenprodil)治疗亚洲H5N1病毒感染的小鼠的研究中,NP-120(Ifenprodil)显著降低了ALI并将存活率提高了40%。亚洲H5N1病毒是迄今为止已知最致命的流感病毒,死亡率超过50%。另一项先前研究还显示,该药物可延长受感染小鼠在缺氧(低氧)条件下的生存期。

 

原始出处:

https://www.firstwordpharma.com/node/1707995

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021678, encodeId=450220216e885, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 01 05:20:53 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539229, encodeId=770b1539229d3, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602247, encodeId=a34e160224e16, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027441, encodeId=59b1102e44125, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 15:20:53 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021678, encodeId=450220216e885, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 01 05:20:53 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539229, encodeId=770b1539229d3, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602247, encodeId=a34e160224e16, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027441, encodeId=59b1102e44125, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 15:20:53 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-03-16 xiaogang319
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021678, encodeId=450220216e885, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 01 05:20:53 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539229, encodeId=770b1539229d3, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602247, encodeId=a34e160224e16, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027441, encodeId=59b1102e44125, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 15:20:53 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-03-16 HNYYM
  4. [GetPortalCommentsPageByObjectIdResponse(id=2021678, encodeId=450220216e885, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 01 05:20:53 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539229, encodeId=770b1539229d3, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602247, encodeId=a34e160224e16, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027441, encodeId=59b1102e44125, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 15:20:53 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-03-16 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2021678, encodeId=450220216e885, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 01 05:20:53 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469157, encodeId=cf1f146915e3d, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539229, encodeId=770b1539229d3, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602247, encodeId=a34e160224e16, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Mar 16 03:20:53 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027441, encodeId=59b1102e44125, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 15:20:53 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-03-14 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

Crit Care:高频振荡通气对急性呼吸窘迫综合征儿童死亡率的影响

由此可见,采用HFOV与PARDS患者28天死亡率增加有关。

抗击疫情在行动!纳米级氧气载体BXT-25治疗急性呼吸窘迫综合征

Bioxytran是一家生物技术公司,旨在使用纳米级氧气载体改善大脑、心脏、肺部和其他重要器官的缺氧状况。Bioxytran正在研究纳米级氧气载体BXT-25治疗由2019-nCoV引起的急性呼吸窘迫综合征(ARDS)。

NEJM:提高动脉血氧分压至90-105mm Hg不能降低急性呼吸窘迫综合征死亡率

急性呼吸窘迫综合征患者,提高动脉血氧分压至90-105mm Hg降低患者死亡率

第32届ESICM:输注维生素C不能改善败血症和急性呼吸窘迫综合征的器官功能障碍评分

根据第32届欧洲重症监护医学会(ESICM)年会上发表的一项研究,在败血症和急性呼吸窘迫综合征(ARDS)患者中输注96小时的维生素C并不能显著改善器官功能障碍评分或改变炎症和血管损伤标志物。弗吉尼亚联邦大学的医学博士Alpha A. Fowler说:“需要进一步的研究来评估维生素C在败血症和ARDS中的潜在作用”。

JAMA:干扰素β对急性呼吸窘迫综合征患者预后的影响

研究认为,静脉注射IFN-β-1a不能降低中重度急性呼吸窘迫综合征死亡以及不使用呼吸机天数

Lancet respir med:急性呼吸窘迫综合征表型简易区分模型研究

研究认为,这一3或4变量简约分类模型可以准确地识别急性呼吸窘迫综合征表型,为患者的精准治疗提供依据

拓展阅读

CMI 山东大学齐鲁医院陈玉国/庞佼佼教授团队揭示ALDH2 rs671基因突变是脓毒症ARDS个体化防治靶点并深入阐明机制

该研究揭示其关键机制为该突变编码的ALDH2缺陷蛋白对中性粒细胞NETs形成过程的抑制作用明显下降,NETs组分导致血管内皮渗漏,从而促进ARDS发生,这为脓毒症ARDS个性化防治提供了新思路。

急性呼吸窘迫综合征患者最佳呼气末正压撤退策略

呼气末正压(PEEP)是治疗急性呼吸窘迫综合征(ARDS)的一种手段。本综述讨论了ARDS急性期后PEEP撤退的各种方法。

Critical Care Medicine:急性呼吸窘迫综合征的心血管亚型

基于TTE参数的LCA在ARDS中确定了四种心血管亚型,它们与目前RVD定义的循环 衰竭机制和死亡率相关性更密切。

急性呼吸窘迫综合征成人患者的最新管理方法

本文更新了之前发布的《急性呼吸窘迫综合征(ARDS)患者管理临床实践指南》,纳入了有关使用皮质类固醇、静脉-静脉体外膜氧合(V-V ECMO)、神经肌肉阻滞剂和呼气末正压(PEEP)的新证据。

脑优先-肺保护性时机机械通气策略

我们提出了一种称为“脑优先-肺保护性时机机械通气策略”的新方法,并介绍了并发 sABI-ARDS 病例的成功经验。

重新定义急性呼吸窘迫综合征(ARDS):观念转变

我们认为ARDS应谨慎诊断。正如危重病领域专家建议的那样,当前基于ARDS的疾病框架应该重新考虑。